Literature DB >> 26352495

Surgical treatment of non-functioning pituitary macroadenomas by the endoscopic endonasal approach in the elderly.

Horacio Armando Marenco1, Samuel Tau Zymberg1, Rodrigo de Paula Santos1, Cláuder Oliveira Ramalho1.   

Abstract

Over the past three decades, surgical series of elderly patients treated for pituitary adenomas have been published, all of which used the microscopic transsphenoidal or transcranial approach. The objective of this study was to retrospectively analyze the surgical results of our first 25 elderly patients with non-functioning pituitary macroadenoma (NFPM) operated by the endoscopic endonasal approach (EEA). Preoperative visual loss was found in 92.8% of the cases, and 70.8% experienced visual improvement following surgery. Preoperative pituitary dysfunction was found in 69.2% of the cases and postoperative pituitary recovery occurred in 22.2% of them. Mean hospital stay was 6.7 days. The results of this study suggest that surgery remains the first line of treatment for NFPM in the elderly. Because age alone is not a barrier for surgery, patients should be selected for surgical treatment based on their symptoms and clinical condition, as defined by comorbidities.

Entities:  

Mesh:

Year:  2015        PMID: 26352495     DOI: 10.1590/0004-282X20150112

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  7 in total

1.  Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series.

Authors:  Alfio Spina; Marco Losa; Pietro Mortini
Journal:  Endocrine       Date:  2019-06-17       Impact factor: 3.633

2.  Quantitative and functional visual field outcomes after endoscopic trans-sphenoidal pituitary adenectomy.

Authors:  Dhruv Parikh; James M W Robins; Tess Garretty; Asim J Sheikh; Atul K Tyagi; Paul A Nix; Nick I Phillips
Journal:  Acta Neurochir (Wien)       Date:  2022-04-15       Impact factor: 2.216

3.  Endoscopic transsphenoidal surgery for biochemically and clinically non-functioning adenohypophyseal tumours in the elderly: experience from a single UK centre.

Authors:  Boon Leong Quah; Andrew Edwards-Bailey; Kanna Gnanalingham; Omar Pathmanaban; Hariclea Vasilopoulos; Federico Roncaroli; Tara Kearney; James Balogun; Konstantina Karabatsou
Journal:  Endocrine       Date:  2021-11-05       Impact factor: 3.633

4.  Surgical Outcomes of Endoscopic Transsphenoidal Pituitary Adenoma Resection in Elderly Versus Younger Patients.

Authors:  Tyler D Alexander; Chandala Chitguppi; Sarah Collopy; Kira Murphy; Pascal Lavergne; Prachi Patel; Tawfiq Khoury; Mindy Rabinowitz; Gurston G Nyquist; Marc R Rosen; Christopher J Farrell; Michael Karsy; James J Evans
Journal:  J Neurol Surg B Skull Base       Date:  2022-01-31

Review 5.  Visual outcomes after endoscopic endonasal pituitary adenoma resection: a systematic review and meta-analysis.

Authors:  Ivo S Muskens; Amir H Zamanipoor Najafabadi; Vanessa Briceno; Nayan Lamba; Joeky T Senders; Wouter R van Furth; Marco J T Verstegen; Timothy R S Smith; Rania A Mekary; Christine A E Eenhorst; Marike L D Broekman
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

6.  Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study.

Authors:  Iris C M Pelsma; Marco J T Verstegen; Friso de Vries; Irene C Notting; Marike L D Broekman; Wouter R van Furth; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2020-08       Impact factor: 4.107

7.  Challenges, Learning Curve, and Safety of Endoscopic Endonasal Surgery of Sellar-Suprasellar Lesions in a Community Hospital.

Authors:  Mohamed A R Soliman; Sydney Eaton; Elise Quint; Abdullah F Alkhamees; Saba Shahab; Avalon O'Connor; Erika Haberfellner; Jacob Im; Abdurrahim A Elashaal; Francis Ling; Mustafa Elbreki; Tommy Dang; Dante J Morassutti; Abdalla Shamisa
Journal:  World Neurosurg       Date:  2020-04-13       Impact factor: 2.104

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.